Hyperoside alleviates myocardial ischemia-reperfusion injury in heart transplantation by promoting mitochondrial fusion via activating the Stat3-Tom70-Opa1 pathway
Collectively, we demonstrated for the first time that hyperoside administration alleviates myocardial IRI by promoting Opa1-mediated mitochondrial fusion <i>in vivo</i> and <i>in vitro</i>. The Tom70-Opa1 pathway was essential for cardioprotective effects of hyperoside treatment. The results in our study indicated that hyperoside or promotion of mitochondrial fusion might be a new potential option for the prevention and treatment of IRI in heart transplantation.
Authors
- Hongwen Lan (ORCID: https://orcid.org/0000-0002-1596-5951)
- Zheng Qiang (ORCID: https://orcid.org/0000-0002-2013-2372)
- Tixiusi Xiong (ORCID: https://orcid.org/0000-0001-8833-1362)
- Kan Wang (ORCID: https://orcid.org/0000-0002-2072-0414)
- Yixuan Wang (ORCID: https://orcid.org/0000-0002-2867-4512)
- Chenghao Li (ORCID: https://orcid.org/0000-0002-9060-9527)
- Jun Hou (ORCID: https://orcid.org/0000-0003-4089-6086)
- Nianguo Dong (ORCID: https://orcid.org/0000-0002-8424-1703)
- Jiawei Shi (ORCID: https://orcid.org/0000-0002-1031-3276)
- Zi-Hao Wang (ORCID: https://orcid.org/0000-0001-6368-2158)
Institutions
- Union Hospital (HK)
- Ministry of Education of the People's Republic of China (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-04
- DOI
- https://doi.org/10.3389/fphar.2025.1566674
- Citations
- 1
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities